Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report released on Monday,Benzinga reports. The firm currently has a $29.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Performance

Shares of NASDAQ IMNN opened at $1.04 on Monday. The firm has a 50 day moving average price of $0.90 and a 200 day moving average price of $0.92. The stock has a market cap of $15.21 million, a P/E ratio of -0.55 and a beta of 1.96. Imunon has a 52-week low of $0.64 and a 52-week high of $3.65.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC raised its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the quarter. Geode Capital Management LLC owned approximately 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.